Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Department of Medicine, Division of Infectious Diseases, University of Louisville School of Medicine, Louisville, KY, USA.
COPD. 2020 Aug;17(4):373-377. doi: 10.1080/15412555.2020.1781805. Epub 2020 Jun 25.
Obesity has been shown to have a paradoxical benefit in a number of conditions, but the long-term effects in obesity after chronic obstructive pulmonary disease (COPD) exacerbation is still unclear. In this study, the effects of obesity on short- and long-term outcomes after a COPD exacerbation were evaluated. This was a secondary analysis of the Rapid Empiric Treatment with Oseltamivir Study (RETOS): a prospective, randomized, unblinded clinical trial. Patients were included in the study if they were hospitalized for acute exacerbation of COPD. Obesity was noted as patients with BMI >30. Clinical outcomes of time to clinical stability, length of stay, and mortality were compared. A total of 301 patients were included in the study, 122 (41%) patients were obese. There was no significant difference in the length of stay and time to clinical stability between patients with and without obesity. Mortality for patients with and without obesity was 3% and 3% at 30 days, 7% and 18% at six months, and 8% and 28% at one year, respectively. After adjusting with multivariable regression analysis, patients with obesity had a significant reduction in odds of dying at one year (adjusted odds ratio (aOR): 0.18; 95% CI: 0.06-0.58; = .004) and at six months (aOR: 0.28; 95% CI: 0.09-0.89; = .031). Our study showed that obesity was associated with reduced mortality at one year and six months after a COPD exacerbation. Although patients with obesity had higher rates of comorbidities, they had reduced mortality at one year after multivariable regression analysis.
肥胖在许多情况下都具有矛盾的益处,但慢性阻塞性肺疾病(COPD)加重后肥胖的长期影响仍不清楚。在这项研究中,评估了肥胖对 COPD 加重后短期和长期结局的影响。这是一项奥司他韦经验性治疗快速研究(RETOS)的二次分析:一项前瞻性、随机、非盲临床试验。如果患者因 COPD 急性加重而住院,则将其纳入研究。肥胖被定义为 BMI>30 的患者。比较了临床稳定时间、住院时间和死亡率等临床结局。共有 301 名患者纳入研究,其中 122 名(41%)患者肥胖。肥胖患者和非肥胖患者的住院时间和临床稳定时间无显著差异。肥胖患者和非肥胖患者的 30 天死亡率分别为 3%和 3%,6 个月死亡率分别为 7%和 18%,1 年死亡率分别为 8%和 28%。在多变量回归分析调整后,肥胖患者在一年(调整后的优势比(aOR):0.18;95%CI:0.06-0.58; = .004)和 6 个月(aOR:0.28;95%CI:0.09-0.89; = .031)死亡的几率显著降低。我们的研究表明,肥胖与 COPD 加重后一年和 6 个月的死亡率降低有关。尽管肥胖患者合并症发生率较高,但在多变量回归分析后,他们的一年死亡率降低。